89bio, Inc. (ETNB) Research

Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.

Market snapshot

Symbol
ETNB
Price
$14.84
Day change
0.00%
Market cap
$2.2B
P/E ratio
-7.78x
52-week range
4.16-15.06
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$17.17

Peer companies

  • Agios Pharmaceuticals, Inc. (AGIO)
  • Beam Therapeutics Inc. (BEAM)
  • Cogent Biosciences, Inc. (COGT)
  • Denali Therapeutics Inc. (DNLI)
  • Galapagos N.V. (GLPG)
  • ImmunityBio, Inc. (IBRX)
  • Liquidia Corporation (LQDA)
  • Ocular Therapeutix, Inc. (OCUL)

Recent insider activity

  • RA CAPITAL MANAGEMENT, L.P. — D-Return (56400 shares) on 2025-10-30
  • RA CAPITAL MANAGEMENT, L.P. — D-Return (45150 shares) on 2025-10-30
  • RA CAPITAL MANAGEMENT, L.P. — D-Return (12500 shares) on 2025-10-30
  • RA CAPITAL MANAGEMENT, L.P. — D-Return (7000 shares) on 2025-10-30
  • RA CAPITAL MANAGEMENT, L.P. — D-Return (7000 shares) on 2025-10-30

Open 89bio, Inc. (ETNB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.